Here, we look at the growing applications of AI-driven spatial imaging techniques in healthcare, focusing on interpreting the 3D genome through cell imaging. AI can assist in understanding intricate data patterns, enabling an improved understanding of cell behaviour and diseases.

Results from a trial conducted in Sweden – the first of its kind – indicated that the use of AI in mammography screening is safe for general practice, and that this could be a huge boost to radiologists.   

Diagnostic biomarkers offer a crucial means of tracking disease spread and progression. Here, we explore their application in age-related diseases, as well as inflammatory diseases such as Crohn’s.

While biomarkers are integral to the identification and validation of disease treatment methods, there is a disconnect between existing validation approaches and their applications in commercialisation.

Advances in spatial imaging have revolutionised disease analysis, revealing new therapeutic targets and biomarkers. However, efficiently interpreting the vast amount of data generated remains a challenge.

Short-read sequencing approaches are highly accurate for small DNA sequences, while long-read sequencing allows for the study of complete genomes without fragmentation. Combining both approaches can address individual constraints and yield more comprehensive results in DNA analysis.

While the cost of genome sequencing has continued to decrease, the present landscape is still too expensive for the true potential of precision medicine to be fully realised. One potentially revolutionary approach involves the use of a mass-produced item to help reduce costs.

Proteins in the brain and plasma of individuals with sporadic Alzheimer’s disease are altered, supporting the hypothesis that plasma biomarkers have utility in predicting early onset in cognitively unimpaired populations.

On-Demand Webinar featuring Didem Arikaya, Sr. Product Manager, Software at 10x Genomics

In modern healthcare, biomarkers are an integral part of approaches to monitoring patient health and condition, providing researchers with a means of predicting treatment response. But what was the first biomarker to be discovered?

The high sensitivity and specificity of ddPCR assays makes the approach well-suited for screening diseases and diagnosing cancer subtypes. Here, we explore some of the ways in which medical researchers are using the technology to pioneer detection of circulating biomarkers for liquid biopsies.

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction.